Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Moodys
Baxter
Harvard Business School

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PBT-1033

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug PBT-1033?

PBT-1033 is an investigational drug.

There have been 5 clinical trials for PBT-1033. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2019.

The most common disease conditions in clinical trials are Esophageal Neoplasms, Migraine Disorders, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are GlaxoSmithKline, xjpfW, and NRG Oncology.

There are seven US patents protecting this investigational drug and sixty-five international patents.

Recent Clinical Trials for PBT-1033
TitleSponsorPhase
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal CancerNational Cancer Institute (NCI)Phase 3
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal CancerNRG OncologyPhase 3
Treatment of Acne Vulgaris Using NAFL in Combination With Isotretinoin and Pricking Blood TherapyxjpfWN/A

See all PBT-1033 clinical trials

Clinical Trial Summary for PBT-1033

Top disease conditions for PBT-1033
Top clinical trial sponsors for PBT-1033

See all PBT-1033 clinical trials

US Patents for PBT-1033

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PBT-1033   Start Trial Parkin ligase activation methods and compositions AN2H DISCOVERY LIMITED (Dublin, IE)   Start Trial
PBT-1033   Start Trial 8-hydroxy quinoline derivatives Prana Biotechnology Limited (AU)   Start Trial
PBT-1033   Start Trial Use of pyridopyrimidine compounds in the treatment of gliomas Prana Biotechnology Limited (Parkville, Victoria, AU)   Start Trial
PBT-1033   Start Trial 8-hydroxy quinoline derivatives Prana Biotechnology Limited (Parkville, Victoria, AU)   Start Trial
PBT-1033   Start Trial Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (Parkville, Victoria, AU)   Start Trial
PBT-1033   Start Trial 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (Parkville, Victoria, AU)   Start Trial
PBT-1033   Start Trial 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (Victoria, AU)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PBT-1033

Drugname Country Document Number Estimated Expiration Related US Patent
PBT-1033 Australia 2015357487 2034-12-05   Start Trial
PBT-1033 Brazil 112017011644 2034-12-05   Start Trial
PBT-1033 Canada 2968094 2034-12-05   Start Trial
PBT-1033 China 107249580 2034-12-05   Start Trial
PBT-1033 European Patent Office 3227437 2034-12-05   Start Trial
PBT-1033 Israel 252425 2034-12-05   Start Trial
PBT-1033 Japan 2017538699 2034-12-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Baxter
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.